Amneal Pharmaceuticals announced that it will transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange. The company expects the Nasdaq listing to occur on December 27, 2023 and will continue to trade under the current symbol “AMRX“. Upon transferring, Amneal will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMRX:
- Amneal Pharmaceuticals announces Ongentys licensing agreement
- Amneal Pharmaceuticals price target raised to $6 from $5 at Barclays
- Amneal Pharmaceuticals raises 2023 adjusted EPS view to 51c-58c from 45c-55c
- Amneal Pharmaceuticals reports Q3 adjusted EPS 19c, consensus 11c
- Amneal Pharmaceuticals rises 17.2%